Does Red Light Therapy Help Herpes?

Red light therapy, more precisely called low-level laser therapy or photobiomodulation, does appear to help with herpes outbreaks based on the clinical trials conducted so far. Studies consistently report faster healing of cold sores, reduced pain, and fewer recurrences after treatment. But there is a significant caveat: the quality of the available evidence is uneven, with most trials suffering from design limitations that make it hard to draw firm conclusions. The research is genuinely encouraging, not just hype, yet it is not yet the kind of bulletproof evidence that would make a doctor prescribe it with the same confidence as an antiviral pill.

What the Healing-Time Studies Actually Found

The most concrete evidence involves cold sores (herpes labialis, caused by HSV-1). Several randomized trials have measured how quickly sores heal under light therapy compared to a placebo or standard treatment. In one controlled trial using 1072 nm infrared light, a single five-minute treatment reduced cold sore healing time to about 4.3 days, compared to 8.5 days for patients using acyclovir cream five times daily.¹ A larger follow-up trial using the same wavelength found the active treatment group healed in a median of about 129 hours (roughly 5.4 days) versus 177 hours (about 7.4 days) for the placebo group.²

A separate trial comparing a diode laser (870 nm) to acyclovir cream found that the laser group recovered in about 2.2 days on average, while the acyclovir group took about 3.4 days.³ Another trial reported that by the fourth day of treatment, the laser-treated group had no remaining lesion surface area at all, while the acyclovir group still averaged over 8 mm² of open sore.⁴ These numbers are surprisingly consistent across different research groups, wavelengths, and protocols: the light-treated group heals faster, often substantially so.

Does It Keep Outbreaks From Coming Back?

For many people with herpes, the more pressing question is not how fast one sore heals but whether they can prevent the next one. This is where some of the most striking findings come in, though they come from small studies. A double-blind, placebo-controlled trial gave patients ten sessions of low-intensity laser treatment and then tracked them for a full year. The laser-treated group had a median recurrence-free interval of 37.5 weeks, while the placebo group managed just 3 weeks before their next outbreak.⁵ That is a dramatic difference, and it has made this study one of the most frequently cited in the field.

A more recent two-year randomized controlled trial tested two different energy doses of photobiomodulation against a placebo. Both laser groups had fewer outbreaks per year and less severe lesions when outbreaks did occur. The lower-energy dose actually performed better for long-term prevention. No patients in either laser group experienced side effects.⁶ That two-year follow-up is rare in light therapy research and lends the finding more weight than a study that only tracks patients for a few weeks.

The going theory is that light therapy modulates the local immune environment in a way that makes reactivation of the dormant virus less likely. Herpes viruses hide in nerve ganglia between outbreaks and emerge when the immune system’s local surveillance dips. If photobiomodulation boosts the cellular immune response in the treated area, it could raise the threshold for reactivation. That mechanism is plausible but not definitively proven in humans, so recurrence prevention remains the most promising but least firmly established benefit.

Pain Relief, Including Post-Herpetic Neuralgia

Pain reduction shows up consistently across trials, sometimes even more reliably than faster healing. When photobiomodulation was added to acyclovir for recurrent cold sores, patients in the combination group reported significantly lower pain at both two and three days after treatment compared to acyclovir alone, and they were more satisfied with their overall treatment experience.⁷ The diode-laser trial mentioned earlier found that pain duration averaged about 1.4 days in the laser group versus 2.3 days for those using acyclovir cream.³

Where the pain story gets especially interesting is with post-herpetic neuralgia, the lingering nerve pain that can follow herpes zoster (shingles) and sometimes persists for months or years. A pilot study using 650 nm laser therapy on post-herpetic neuralgia patients found that 11 out of 15 patients achieved a final pain score of zero, even though most started with severe pain. None reported recurrence of pain in the months after treatment ended.⁸ A larger study found that when low-level laser was applied during the acute shingles phase, the odds of developing post-herpetic neuralgia afterward dropped dramatically at one, three, and six months compared to a control group.⁹ These are small studies, but the effect sizes are large enough that the finding is hard to dismiss.

What About Genital Herpes?

Most of the research focuses on oral herpes (HSV-1 cold sores), partly because cold sores are easy to study in a clinic setting. Evidence for genital herpes (usually HSV-2) is thinner but points in the same direction. A study on recurrent genital herpes using photodynamic therapy found that skin lesions healed in about 5.4 days in the treated group versus 7.2 days without treatment. More strikingly, the recurrence rate after treatment was about 37.5% in the photodynamic therapy group compared to roughly 71% in the control group.¹⁰

It is worth noting that this study used photodynamic therapy, which involves applying a light-activated chemical (a photosensitizer) to the skin before shining the light. That is a different protocol from straight photobiomodulation, where no chemical is used. Both involve light, but the mechanism differs: photodynamic therapy generates reactive oxygen species that can directly damage viral particles in the tissue, while photobiomodulation works by stimulating cellular processes. For genital herpes in particular, most of the published work uses the photodynamic approach rather than plain red light alone.

How It Stacks Up Against Antiviral Medications

Acyclovir and its relatives (valacyclovir, famciclovir) are the standard treatment for herpes outbreaks. They work by blocking the virus’s ability to replicate. In head-to-head comparisons, light therapy has actually outperformed topical acyclovir cream in several trials, producing faster healing and shorter pain duration.⁴ This is less surprising than it sounds: topical acyclovir cream is not the strongest form of antiviral therapy. It modestly shortens cold sore duration by about a day. Oral antivirals are more effective, and no published trials have compared light therapy to oral valacyclovir directly.

A randomized controlled trial tested what happens when you combine the two approaches. Patients who received photobiomodulation alongside acyclovir had smaller lesions and less pain than those using acyclovir alone.⁷ This suggests the two treatments work through different enough pathways that they complement each other. Someone already taking oral antivirals might benefit from adding light therapy on top, though no trial has tested that specific combination yet.

Combining Light Therapy with Photosensitizers

Some of the best results in recent research come from pairing light therapy with a photosensitizing agent, a dye like methylene blue that is applied to the sore before treatment. When the light hits the dye, it triggers a photochemical reaction that generates compounds toxic to viruses and bacteria on the skin’s surface. This antimicrobial photodynamic therapy, combined with standard photobiomodulation, outperformed both acyclovir alone and plain photobiomodulation alone in a recent randomized trial. Healing time averaged about 3.2 days in the combination group, compared to about 4 days for photobiomodulation alone and 4.75 days for acyclovir cream.¹¹ Pain scores were also significantly lower in the combination group at multiple time points.

A narrative review of the broader herpesvirus literature echoed this, concluding that combining laser treatment on the skin with topical antivirals produced the best outcomes across the studies reviewed.¹² The photosensitizer approach is only done in a clinical setting since it requires precise application and dosing, but it represents where the research seems to be heading for maximum effectiveness.

The Evidence Quality Problem

Here is where the optimism needs to be tempered. Multiple systematic reviews have flagged a recurring issue: most of these trials have a high risk of bias. A 2022 meta-analysis found that only one of the included studies had a low risk of bias, and while the pooled results favored laser therapy, the reviewers stressed that better-designed trials are needed.¹³ A 2025 meta-analysis of randomized controlled trials similarly found high overall risk of bias across the five included studies.¹⁴

An earlier systematic review had assessed six eligible trials and noted extreme variability in study designs: wavelengths ranged from 632.5 to 870 nm, power outputs from 5 to 80 watts, and energy densities from about 2 to 48 joules per square centimeter. All six found laser therapy effective, and none reported side effects, but the reviewers concluded that the inconsistency in parameters made it impossible to pool the data statistically or recommend a standard protocol.¹⁵

What does “high risk of bias” mean in practical terms? It often comes down to issues like small sample sizes, inconsistent blinding (it is hard to fake a laser treatment convincingly), and lack of standardized outcome measures. It does not mean the results are wrong, but it does mean a well-funded, properly blinded trial could conceivably find a smaller effect than the current literature suggests. The direction of the effect, meaning that light therapy helps, is consistent enough across studies that it is probably real. The magnitude of the benefit remains genuinely uncertain.

Clinical Lasers Versus Home Devices

Almost all of the positive results described above come from clinical-grade laser diodes operated by trained clinicians. The devices used in these studies deliver specific wavelengths at calibrated power outputs, applied at precise distances and durations. A typical clinical protocol might use an 870 nm diode laser at an energy density of 4.5 joules per square centimeter, held 6-8 mm from the lesion for one minute per session.¹⁶

Consumer red light therapy devices, the LED panels and handheld wands sold online, are a different animal. Most use LEDs rather than laser diodes, which means the light is less focused and delivers energy over a wider area. Their power output is typically lower, and many do not specify their actual energy density or irradiance in terms that map onto the clinical literature. Some consumer devices marketed for cold sores do use near-infrared wavelengths in the right range, but whether they deliver enough energy to the tissue to replicate clinical results is an open question. No one has run a randomized controlled trial comparing a consumer panel to the clinical-grade lasers used in the published research.

This gap matters because photobiomodulation follows what researchers call a biphasic dose response: too little light does nothing, the right amount helps, and too much can actually be counterproductive. A device that delivers a fraction of the studied dose might not clear the threshold for any benefit, while one that delivers too much to too broad an area might heat tissue without triggering the desired cellular response. If you are considering a home device, the research cannot tell you it will work the same way as the lasers in these trials.

When to Start Treatment

Timing appears to matter. Several study protocols specifically targeted the prodromal stage, the tingling or burning sensation that precedes a visible cold sore by hours to a day or two. One protocol applied 670 nm laser irradiation during the prodromal stage at a lower energy dose, then switched to a higher dose if the outbreak progressed to the crust or secondary-infection stage.¹⁷ This mirrors what we know about antiviral medications: starting acyclovir at the first tingle is more effective than waiting until blisters have formed.

The post-herpetic neuralgia data reinforces this principle from the opposite end. In the study on shingles-related nerve pain, patients who received laser treatment during the acute phase of the rash had dramatically lower odds of developing long-term neuralgia compared to those treated later or not at all.⁹ Early intervention was the key variable. For anyone exploring light therapy for herpes, the consistent message across the literature is that sooner is better.

Herpes Zoster and Other Herpes-Family Conditions

Herpes simplex (HSV-1 and HSV-2) gets the most research attention for light therapy, but herpes zoster (shingles, caused by varicella-zoster virus) has also been studied. A pilot study on herpes zoster ophthalmicus, shingles affecting the eye area, found that patients who received 830 nm LED therapy healed in about 13 days compared to about 16 days in the control group. Pain scores improved faster in the light-therapy group from day four onward, though the overall pain difference did not quite reach statistical significance in that small sample.

This is relevant because the herpes virus family shares structural and behavioral similarities. All herpesviruses establish latency in nerve tissue and reactivate under stress or immune suppression. If photobiomodulation’s benefits come primarily from modulating the local immune response and reducing inflammation rather than from directly attacking the virus, the therapy could theoretically help across multiple herpesvirus conditions. That hypothesis is far from proven across the board, but the early signals from shingles research are consistent with the cold sore data.

Safety and Who Should Be Cautious

Across every trial reviewed in multiple systematic analyses, no side effects from photobiomodulation were reported.¹⁵ That is a genuinely good safety profile, especially compared to long-term oral antiviral suppression, which carries a small risk of kidney issues and headaches. Light therapy at the wavelengths and power levels used in these studies does not burn tissue, does not interact with medications, and does not appear to cause photosensitivity reactions in the absence of a photosensitizer.

People who should exercise caution include anyone with a photosensitivity disorder, anyone taking medications that increase light sensitivity (certain antibiotics, retinoids), and anyone with a skin cancer or precancerous lesion in the treatment area. The photodynamic therapy approach, with its photosensitizing dyes, introduces a separate set of considerations: the dye itself can cause temporary staining and mild irritation, and the reactive oxygen species it generates could theoretically damage healthy tissue if the protocol is not carefully controlled. That approach should remain strictly clinical rather than DIY.

For immunocompromised individuals, who often suffer more frequent and severe herpes outbreaks, there is an interesting theoretical argument for light therapy as an adjunct since it does not rely on suppressing viral replication the way antivirals do. But this population is also underrepresented in the trials, so the evidence base is thin. If you have a weakened immune system and frequent outbreaks, light therapy is worth discussing with your doctor, but the standard antiviral regimen remains the first-line treatment with far more data behind it.